Chugai Looks Overseas As Challenges Loom At Home
Chugai sees continued overseas growth, helped by sales through parent and licensee Roche and a brace of novel products, as key to overcoming challenges at home over the next few years.
You may also be interested in...
Shire puts in solid results in last full year before Takeda acquisition, with 4% sales growth and strong cash flow, but there was some weakness in hematology stemming from lower ex-US prices and rising competition.
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.